Abstract
Breast cancer is the leading cause of cancer-related death in women worldwide. Invasive ductal carcinoma (IDC) is the most frequent invasive form of breast cancer followed by metastasis. There is no accepted marker for distinguishing this form from other less aggressive forms of breast cancer. Therefore, finding new markers especially molecularly detectable ones are noteworthy. It has been shown that NOTCH1 has been overexpressed in the patients with breast cancer, but no study has investigated the expression of NOTCH1 and its correlation with other molecular and hormonal markers of breast cancer so far. In the current study, 20 breast cancer tissues and 20 matched adjacent normal breast tissue from breast cancer patients were obtained and categorized in two groups: patients with IDC and patient with other types of breast cancer. Gene expression analysis using real-time PCR showed that the NOTCH1 gene was significantly overexpressed in patients with IDC. We also found a slight correlation between NOTCH1 overexpression and p53 accumulation in the cancerous cells confirmed by Immunohistochemistry (IHC). This results showed that it is possible to introduce NOTCH1 expression as a novel biomarker of IDC, alone or preferably accompanied by IHC of p53. We also can design new therapeutic agents targeting NOTCH1 expression for inhibition of metastasis in ductal breast carcinoma.
Highlights
Breast cancer is the most common malignancy in women worldwide
We performed real-time PCR to relatively quantify the changes in NOTCH1 expression at mRNA level in breast cancer clinical samples
We divided patient into two subgroups based on histopathological reports; patients diagnosed with Invasive ductal carcinoma (IDC) and patients diagnosed to have other types of breast cancer
Summary
Breast cancer is the most common malignancy in women worldwide. Despite the improvements in therapies for breast cancer such as chemotherapy, radiotherapy and hormone therapy, recurrent rates are high (Weigelt et al 2005; Rad et al 2015). Two important factors that make a treatment successful in breast cancer are early diagnosis and prognosis (Turner et al 2014). There is always a lacuna in the diagnosis of breast cancer at early stages (Donepudi Ms Fau-Kondapalli et al 2014). Specific gene expression signatures have been used to create new tests that could offer better prognosis than the traditional diagnostic methods. New molecular markers are needed as prognostic tools in breast cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
